https://scholars.lib.ntu.edu.tw/handle/123456789/612552
標題: | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | 作者: | Kim R.D. Sarker D. Meyer T. Yau T. Macarulla T. Park J.-W. Choo S.P. Hollebecque A. Sung M.W. Lim H.-Y. Mazzaferro V. Trojan J. Zhu A.X. Yoon J.-H. Sharma S. ZHONG-ZHE LIN Chan S.L. Faivre S. Feun L.G. Yen C.-J. Dufour J.-F. Palmer D.H. Llovet J.M. Manoogian M. Tugnait M. Stransky N. Hagel M. Kohl N.E. Lengauer C. Sherwin C.A. Schmidt-Kittler O. Hoeflich K.P. Shi H. Wolf B.B. Kang Y.-K. |
公開日期: | 2019 | 出版社: | American Association for Cancer Research Inc. | 卷: | 9 | 期: | 12 | 起(迄)頁: | 1696-1707 | 來源出版物: | Cancer Discovery | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075943998&doi=10.1158%2f2159-8290.CD-19-0555&partnerID=40&md5=6ae9258a7fde1efd3ed825e0be1be41d https://scholars.lib.ntu.edu.tw/handle/123456789/612552 |
ISSN: | 2159-8274 | DOI: | 10.1158/2159-8290.CD-19-0555 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。